Clinical TrialJul 1, 2026, 08:43 AM
Artelo Biosciences Reports Positive Preclinical Data for ART26.12
AI Summary
Artelo Biosciences announced positive new preclinical data for its lead drug candidate, ART26.12, demonstrating its efficacy in alleviating neuropathic pain associated with spinal cord injury in an animal model. These findings, presented at a scientific symposium, support the broad therapeutic potential of ART26.12 as a differentiated, non-opioid approach to treating chronic pain and inflammatory disorders. The company believes these results strengthen the scientific rationale for ART26.12, which is currently in Phase 1 development.
Key Highlights
- Artelo Biosciences announced positive preclinical data for ART26.12 in neuropathic pain from spinal cord injury.
- The findings were presented at the International Cannabinoid Research Society 2026 Annual Symposium.
- ART26.12 is a clinical-stage selective fatty acid binding protein 5 (FABP5) inhibitor.
- Preclinical study showed FABP5 inhibition alleviated neuropathic pain in an animal model.
- Results demonstrated ART26.12 reduced mechanical hypersensitivity and decreased spontaneous pain-related behaviors.
- The drug also suppressed nociceptor hyperexcitability and improved pain outcomes after oral administration.
- ART26.12 is currently in Phase 1 development and has shown a favorable safety profile in human studies.
Price Impact
More from ARTL